Kobe University Repository : Thesis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Characterization of a Pediatric T-Cell Acute Lymphoblastic Leukemia Patient with Simultaneous LYL1 and LMO2 Rearrangements
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Articles and Brief Reports Acute Lymphoblastic Leukemia Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements Irene Homminga, 1 Maartje J. Vuerhard, 1 Anton W. Langerak, 2 Jessica Buijs-Gladdines, 1 Rob Pieters, 1 and Jules P.P. Meijerink 1 1Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam; and 2Department of Immunology, Erasmus MC, Rotterdam, The Netherlands ABSTRACT Translocation of the LYL1 oncogene are rare in T-cell acute consistently clustered along with cases having TAL1 or lymphoblastic leukemia, whereas the homologous TAL1 LMO2 rearrangements. Therefore, LYL1 -rearranged cases are gene is rearranged in approximately 20% of patients. not necessarily associated with immature T-cell develop - Previous gene-expression studies have identified an imma - ment, despite high LYL1 levels, but elicit a TALLMO expres - ture T-cell acute lymphoblastic leukemia subgroup with high sion signature. LYL1 expression in the absence of chromosomal aberrations. Molecular characterization of a t(7;19)(q34;p13) in a pediatric Key words: T-ALL, pediatric, LYL1, LMO2, rearrangements. T-cell acute lymphoblastic leukemia patient led to the identi - fication of a translocation between the TRB@ and LYL1 loci. Citation: Homminga I, Vuerhard MJ, Langerak AW, Buijs- Similar to incidental T-cell acute lymphoblastic leukemia Gladdines J, Pieters R, and Meijerink JPP. Characterization of a cases with synergistic, double translocations affecting pediatric T-cell acute lymphoblastic leukemia patient with simul - TAL1/2 and LMO1/2 oncogenes, this LYL1 -translocated taneous LYL1 and LMO2 rearrangements. -
Gene Section Short Communication
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST -CNRS Gene Section Short Communication SSX2IP (synovial sarcoma, X breakpoint 2 interacting protein) Ghazala Khan, Barbara Guinn University of Bedfordshire, Division of Science, Park Square, Luton, Bedfordshire, UK (GK), University of Bedfordshire, Division of Science, Park Square, Luton, Bedfordshire, UK; Cancer Sciences Unit, University of Southampton, Southampton, UK; Department of Haematological Medicine, Kings College, London, UK (BG) Published in Atlas Database: March 2012 Online updated version : http://AtlasGeneticsOncology.org/Genes/SSX2IPID42407ch1p22.html DOI: 10.4267/2042/47489 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology exons however the first one is not translated (de Bruijn Identity et al., 2002). Other names: ADIP Transcription HGNC (Hugo): SSX2IP The gene contains 33 introns. 18 different mRNAs are Location: 1p22.3 produced; 17 spliced and 1 un-spliced form (Thierry- Note Mieg and Thierry-Mieg, 2006). SSX2IP gene encodes the protein SSX2IP which Pseudogene interacts with the cancer-testis antigen SSX2. It is A pseudogene of this gene is found on chromosome 3 thought that SSX2IP regulates the function of SSX2 in (provided by RefSeq, Oct 2009 from Entrez Gene). the testes and malignant cells. The rodent equivalent is known as afadin DIL domain-interacting protein (ADIP) and the chicken orthologue is called clock- Protein controlled gene (LCG) (Breslin et al., 2007). Note SSX2IP was discovered due to its interaction with DNA/RNA SSX2 in a yeast two-hybrid system and believed to regulate the function of SSX2 in the testes and Note malignant cells (de Bruijn et al., 2002). -
The Role of Noncoding Mutations in Blood Cancers Sunniyat Rahman and Marc R
© 2019. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2019) 12, dmm041988. doi:10.1242/dmm.041988 REVIEW The role of noncoding mutations in blood cancers Sunniyat Rahman and Marc R. Mansour* ABSTRACT survival in adult acute myeloid leukaemia (AML) and ALL are The search for oncogenic mutations in haematological malignancies still less than 50%, with significant treatment challenges including has largely focused on coding sequence variants. These variants treatment-resistant disease, clonal heterogeneity of the underlying have been critical in understanding these complex cancers in greater disease, treatment-associated toxicities and poor tolerance for detail, ultimately leading to better disease monitoring, subtyping and intensive treatment regimens, particularly in older patients with prognostication. In contrast, the search for oncogenic variants in the comorbidities (Kansagra et al., 2018). Because of this, there is a noncoding genome has proven to be challenging given the vastness significant impetus to discover new genetic aberrations, including of the search space, the intrinsic difficulty in assessing the impact of driver mutations (see Box 1 for a glossary of terms), that may variants that do not code for functional proteins, and our still primitive provide insight into the mechanisms of malignant haematopoiesis, understanding of the function harboured by large parts of the as well as offering novel therapeutic opportunities. noncoding genome. Recent studies have broken ground on this Detailed genetic characterisation of haematological malignancies quest, identifying somatically acquired and recurrent mutations in the has already identified alterations that are now being used for better noncoding genome that activate the expression of proto-oncogenes. diagnosis, prognostication, subtype identification and to inform In this Review, we explore some of the best-characterised examples therapeutic decisions (Taylor et al., 2017). -
Epha2 Proteomics in Human Keratinocytes Reveals a Novel Association with Afadin and Epidermal Tight Junctions Bethany E
© 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 111-118 doi:10.1242/jcs.188169 SPECIAL ISSUE: 3D CELL BIOLOGY SHORT REPORT EphA2 proteomics in human keratinocytes reveals a novel association with afadin and epidermal tight junctions Bethany E. Perez White1, Rosa Ventrella1, Nihal Kaplan1, Calvin J. Cable1, Paul M. Thomas2,3 and Spiro Getsios1,4,*,‡ ABSTRACT EphA2 increased susceptibility to chemically-induced skin EphA2 is a receptor tyrosine kinase that helps to maintain epidermal carcinogenesis (Guo et al., 2006), whereas ephrin-targeting of tissue homeostasis. A proximity-dependent biotin identification (BioID) EphA2 enhanced keratinocyte adhesion and differentiation (Lin approach was used to identify proteins in close proximity to EphA2 et al., 2010; Walsh and Blumenberg, 2011). EphA2 can positively within primary human keratinocytes and three-dimensional (3D) or negatively regulate intercellular junctions, including tight reconstituted human epidermis (RHE) cultures to map a putative junctions (Zhou et al., 2011; Tanaka et al., 2005; Larson et al., protein interaction network for this membrane receptor that exhibits a 2008; Miao et al., 2014; Miura et al., 2009) that contribute to skin polarized distribution in stratified epithelia. Although a subset of known barrier function (Niessen, 2007). Importantly, EphA2 is expressed EphA2 interactors were identified in the BioID screen, >97% were in a differentiation-dependent, polarized manner within human uniquely detected in keratinocytes with over 50% of these vicinal epidermis (Fig. 1A). proteins only present in 3D human epidermal culture. Afadin (AFDN), a We adapted the method of unbiased, proximity-dependent biotin cytoskeletal and junction-associated protein, was present in 2D and 3D identification (BioID) (Roux et al., 2012) to identify near neighbors keratinocyte cultures, and validated as a so-far-unknown EphA2- of EphA2 in normal human epidermal keratinocytes (NHEKs) 2+ interacting protein. -
Afadin, a Ras/Rap Effector That Controls Cadherin Function, Promotes Spine and Excitatory Synapse Density in the Hippocampus
The Journal of Neuroscience, January 4, 2012 • 32(1):99–110 • 99 Development/Plasticity/Repair Afadin, A Ras/Rap Effector That Controls Cadherin Function, Promotes Spine and Excitatory Synapse Density in the Hippocampus Gerard M. J. Beaudoin III,1 Claude M. Schofield,2* Tulip Nuwal,3* Keling Zang,1 Erik M. Ullian,1,2† Bo Huang,3† and Louis F. Reichardt1,4 Departments of 1Physiology, 2Opthamology, 3Pharmaceutical Chemistry, and 4Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94158 Many molecules regulate synaptogenesis, but intracellular signaling pathways required for their functions are poorly understood. Afadin is a Rap-regulated, actin-binding protein that promotes cadherin complex assembly as well as binding many other cell adhesion mole- cules and receptors. To examine its role in mediating synaptogenesis, we deleted afadin (mllt1), using a conditional allele, in postmitotic hippocampal neurons. Consistent with its role in promoting cadherin recruitment, afadin deletion resulted in 70% fewer and less intense N-cadherin puncta with similar reductions of -catenin and ␣N-catenin puncta densities and 35% reduction in EphB2 puncta density. Its absence also resulted in 40% decreases in spine and excitatory synapse densities in the stratum radiatum of CA1, as determined by morphology, apposition of presynaptic and postsynaptic markers, and synaptic transmission. The remaining synapses appeared to function normally. Thus, afadin is a key intracellular signaling molecule for cadherin recruitment and is necessary for spine and synapse formation in vivo. Introduction 2007). In Drosophila, absence of N-cadherin prevents normal Synapses are formed at contacts between neurons as a result of synapse formation between photoreceptor axons and their tar- intercellular interactions that result in stepwise assembly of syn- gets (Clandinin and Feldheim, 2009). -
LMO T-Cell Translocation Oncogenes Typify Genes Activated by Chromosomal Translocations That Alter Transcription and Developmental Processes
Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press PERSPECTIVE LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes Terence H. Rabbitts1 Medical Research Council (MRC) Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Cambridge CB2 2QH, UK The cytogenetic analysis of tumors, particularly those of ment (immunoglobulin or T-cell receptor) occurs and oc- hematopoietic origin, has revealed that reciprocal chro- casionally mediates chromosomal translocation. This mosomal translocations are recurring features of these type of translocation causes oncogene activation result- tumors. Further from the initial recognition of the trans- ing from the new chromosomal environment of the re- location t(9;22) (Nowell and Hungerford 1960; Rowley arranged gene. In general, this means inappropriate gene 1973), it has become clear that particular chromosomal expression. The second, and probably the most common translocations are found consistently in specific tumor outcome of chromosomal translocations, is gene fusion subtypes. A principle example of this is the translocation in which exons from a gene on each of the involved chro- t(8;14)(q24;q32.1) invariably found in the human B cell mosomes are linked after the chromosomal transloca- tumor Burkitt’s lymphoma (Manolov and Manolov 1972; tion, resulting in a fusion mRNA and protein. This type Zech et al. 1976). The link with the immunoglobulin of event is found in many cases of hematopoietic tumors H-chain locus on chromosome 14, band q32.1 (Croce et and in the sarcomas. al. 1979; Hobart et al. -
Rap1 Acts Via Multiple Mechanisms to Position Canoe/Afadin and Adherens Junctions and Mediate Apical-Basal Polarity Establishment
bioRxiv preprint doi: https://doi.org/10.1101/170977; this version posted July 31, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Rap1 acts via multiple mechanisms to position Canoe/Afadin and adherens junctions and mediate apical-basal polarity establishment Teresa T. Bonello1, Kia Z. Perez-Vale2, Kaelyn D. Sumigray3, and Mark Peifer1,2,3* 1 Department of Biology, University of North Carolina at Chapel Hill, CB#3280, Chapel Hill, NC 27599-3280, USA 2 Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Running Title Active Rap1 positions Canoe and AJs 6950 words * To whom correspondence should be addressed Email: [email protected] Phone: (919) 962-2272 Abbreviations used: α-cat, alpha-catenin; β-cat, beta-catenin; AJ, adherens junction; Arm, Armadillo; Baz, BazooKa; CA, constitutively active; Cno, Canoe; DE-cad, Drosophila E-cadherin; Dzy, Dizzy; GAP, GTPase activating protein; GDP, guanosine diphosphate; GEF, guanine nucleotide exchange factor; GFP, green fluorescent protein; GTP, guanosine triphosphate; IF, immunofluorescence; MIP, maximum intensity projection; RA, Ras-associated; RFP, red fluorescent protein; SAJ, spot adherens junction; shRNA, short hairpin RNA; TCJ, tricellular junction; WT, wildtype 1 bioRxiv preprint doi: https://doi.org/10.1101/170977; this version posted July 31, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. -
A Previously Unrecognized Promoter of LMO2 Forms Part of A
Oncogene (2010) 29, 5796–5808 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients SH Oram1, JAI Thoms2, C Pridans1, ME Janes2, SJ Kinston1, S Anand1, J-R Landry3, RB Lock4, P-S Jayaraman5, BJ Huntly1, JE Pimanda2 and B Go¨ttgens1 1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; 2Lowy Cancer Research Centre and The Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia; 3Institute for Research in Immunology and Cancer, Universite´ de Montre´al, Montre´al, Quebec, Canada; 4Children’s Cancer Institute Australia, University of New South Wales, Sydney, New South Wales, Australia and 5Birmingham University Stem Cell Centre, University of Birmingham, Edgbaston, Birmingham, UK The T-cell oncogene Lim-only 2 (LMO2) critically Introduction influences both normal and malignant haematopoiesis. LMO2 is not normally expressed in T cells, yet ectopic Lim-only 2 (LMO2), also known as TTG2 or RBTN2, expression is seen in the majority of T-acute lympho- was originally reported as a T-cell oncogene where it blastic leukaemia (T-ALL) patients with specific translo- was recurrently rearranged by chromosomal transloca- cations involving LMO2 in only a subset of these patients. tion in T-cell malignancies (Boehm et al., 1991; Royer- Ectopic lmo2 expression in thymocytes of transgenic mice Pokora et al., 1991). LMO2 encodes a 156 amino-acid causes T-ALL, and retroviral vector integration into the transcriptional co-factor containing two LIM domain LMO2 locus was implicated in the development of clonal zinc-fingers (Kadrmas and Beckerle, 2004) that do not T-cell disease in patients undergoing gene therapy. -
Letters to the Editor
LETTERS TO THE EDITOR The significant upregulation of Gata1 and EpoR mRNA Mice over-expressing human erythropoietin expression in hEPO over-expressing tg6 mice was con - indicate that erythropoietin enhances expression firmed by analyzing the spleen as a major source of of its receptor via up-regulated Gata1 and Tal1 hematopoiesis (Figure 2A and B). To further dissect the complexity of changes in the transcriptional network, the analysis of Myb mRNA expression served as marker for The development of medullary hematopoiesis is char - adult definitive erythroblasts, 10 showing significantly acterized by a specific expression profile of hematopoiet - ic transcription factors, including GATA transcription fac - tors. At mid-gestation, when hematopoiesis is newly A GATA 1 2 established in the bone marrow of human fetuses, initial - wt ly high GATA2 expression becomes subsequently down- regulated, while GATA1 expression increases in parallel. 1 1.5 Both transcription factors bind to overlapping sets of tg6 hematopoietic downstream target genes, often at distinct 1 sites, to regulate the balance between proliferation and differentiation. Chromatin occupancy by GATA1 and 0.5 GATA2 can change in the course of hematopoietic differ - entiation, leading to the so-called GATA switch. 2 Thus, a 0 n d7 d21 d49 i spatio-temporal regulation of GATA1 or GATA2 activities t c is required within lineage-specific differentiation. During a - erythroid differentiation GATA1 expression peaks at the b B GATA 2 3 o level of colony-forming units (CFU-E), where erythro - t 2 e poietin (Epo) exerts most specifically its effects, but v i t blocks terminal maturation if constitutively over- a 1.5 l 4 e expressed. -
Rahman Et Al 2017 Somatically Acquired Activation of LMO2 in T-ALL
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Rahman, Sunniyat, Michael Magnussen, Theresa E. León, Nadine Farah, Zhaodong Li, Brian J. Abraham, Krisztina Z. Alapi, et al. “Activation of the LMO2 Oncogene through a Somatically Acquired Neomorphic Promoter in T-Cell Acute Lymphoblastic Leukemia.” Blood 129, no. 24 (March 7, 2017): 3221–3226. As Published https://doi.org/10.1182/blood-2016-09-742148 Publisher American Society of Hematology Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/117283 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ 1 Activation of the LMO2 oncogene through a somatically acquired 2 neomorphic promoter in T-Cell Acute Lymphoblastic Leukemia 3 4 Sunniyat Rahman1, Michael Magnussen1, Theresa E. León1, Nadine Farah1, Zhaodong Li2, 5 Brian J Abraham3, Krisztina Z. Alapi1, Rachel J. Mitchell1, Tom Naughton1, Adele K. 6 Fielding1, Arnold Pizzey1, Sophia Bustraan1, Christopher Allen1, Teodora Popa , Karin Pike- 7 Overzet5, Laura Garcia-Perez5, Rosemary E. Gale1, David C. Linch1, Frank J.T. Staal5, 8 Richard A. Young3,4, A. Thomas Look2,6, Marc R. Mansour1 9 10 1. University College London Cancer Institute, Department of Haematology, 72 Huntley 11 Street, London. WC1E 6DD. United Kingdom. 12 2. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical 13 School, Boston, MA 02215 14 3. Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 15 02142 16 4. -
Vinexin Family (SORBS) Proteins Play Different Roles in Stiffness- Sensing and Contractile Force Generation Takafumi Ichikawa1,2, Masahiro Kita1, Tsubasa S
© 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 3517-3531 doi:10.1242/jcs.200691 RESEARCH ARTICLE Vinexin family (SORBS) proteins play different roles in stiffness- sensing and contractile force generation Takafumi Ichikawa1,2, Masahiro Kita1, Tsubasa S. Matsui3,4, Ayaka Ichikawa Nagasato1, Tomohiko Araki3, Shian-Huey Chiang5, Takuhito Sezaki1, Yasuhisa Kimura1, Kazumitsu Ueda1,2, Shinji Deguchi3,4, Alan R. Saltiel5,* and Noriyuki Kioka1,2,‡ ABSTRACT generating actin stress fibers (SFs) (Geiger et al., 2001). This Vinexin, c-Cbl associated protein (CAP) and Arg-binding protein 2 ‘ ’ (ArgBP2) constitute an adaptor protein family called the vinexin mechanical linkage acts as a molecular clutch to transmit the force (SORBS) family that is targeted to focal adhesions (FAs). Although derived from non-muscle myosin-II-dependent contraction to the numerous studies have focused on each of the SORBS proteins and ECM. Cells on more rigid substrates exert greater contractile forces partially elucidated their involvement in mechanotransduction, a than those on soft substrates (Hoffman et al., 2011; Roca-Cusachs comparative analysis of their function has not been well addressed. et al., 2012; LaCroix et al., 2015). These alterations can lead to Here, we established mouse embryonic fibroblasts that individually stiffness-dependent biochemical signals. Among the numerous FA scaffolding proteins, vinculin is one of expressed SORBS proteins and analysed their functions in an ‘ ’ identical cell context. Both vinexin-α and CAP co-localized with the main clutch molecules that can regulate force transmission. vinculin at FAs and promoted the appearance of vinculin-rich FAs, Vinculin consists of an N-terminal head region and a C-terminal tail α region separated by a flexible proline-rich linker region (Bakolitsa whereas ArgBP2 co-localized with -actinin at the proximal end of – FAs and punctate structures on actin stress fibers (SFs), and induced et al., 2004; Borgon et al., 2004). -
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia
cancers Article T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker Magda Zanelli 1 , Giuseppe G. Loscocco 2,3 , Elena Sabattini 4, Maurizio Zizzo 5,6,* , Francesca Sanguedolce 7, Luigi Panico 8, Daniela Fanni 9, Raffaella Santi 10, Cecilia Caprera 11, Cristiana Rossi 12, Alessandra Soriano 13,14, Alberto Cavazza 1, Alessandro Giunta 5, Cristina Mecucci 15, Alessandro M. Vannucchi 2,3, Stefano A. Pileri 16 and Stefano Ascani 11,15 1 Pathology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; [email protected] (M.Z.); [email protected] (A.C.) 2 Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy; gloscocco@unifi.it (G.G.L.); a.vannucchi@unifi.it (A.M.V.) 3 Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero-Universitaria Careggi, 50139 Florence, Italy 4 Citation: Zanelli, M.; Loscocco, G.G.; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; Sabattini, E.; Zizzo, M.; [email protected] 5 Sanguedolce, F.; Panico, L.; Fanni, D.; Surgical Oncology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; [email protected] Santi, R.; Caprera, C.; Rossi, C.; et al. 6 Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, T-Cell Lymphoblastic Lymphoma 41121 Modena, Italy Arising in the Setting of 7 Pathology Unit, Azienda Ospedaliero-Universitaria—Ospedali Riuniti di Foggia, 71122 Foggia, Italy; Myeloid/Lymphoid Neoplasms with [email protected] Eosinophilia: LMO2 8 Pathology Unit Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, P.O.